AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36791089
Drug: Self-applied treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-applied treatment for rat phobia supported by a Virtual Therapy Assistant (VTA)
Trial: 36791161
Drug: Ad26.RSV.preF-RSV preF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.RSV.preF-RSV preF protein vaccine
Trial: 39052726
Drug: RSVPreF3 OA
RxNorm normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVPreF3 OA vaccine
Trial: 36791162
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine (3-μg dose)
Trial: 36791792
Drug: Age-related dose
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-related dose adjustments
Trial: 36791986
Drug: Placebo (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (40 mL of normal saline solution)
Trial: 36792639
Drug: 0.5% isobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% isobaric bupivacaine (3 ml)
Trial: 36792639
Drug: 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levobupivacaine (3 ml)
Trial: 36792639
Drug: 0.5% hyperbaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% hyperbaric bupivacaine (3 ml)
Trial: 36792805
Drug: Lisavanbulin administered
RxNorm normalized name: Lisavanbulin
DrugBank: Lisavanbulin (DB15224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisavanbulin administered as a 48-hour intravenous infusion at the recommended Phase 2 dose (RP2D) of 70 mg/m²
Trial: 36793000
Drug: ESPB (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESPB (20 ml 0.25% bupivacaine)
Trial: 36793000
Drug: ESPB +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESPB + DEX (19 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 µg/kg)
Trial: 36793118
Drug: baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: baricitinib 4 mg per day + hydroxychloroquine (HCQ) 400 mg per day
Trial: 36793118
Drug: hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroxychloroquine (HCQ) 400 mg per day alone
Trial: 36794354
Drug: Idecabtagene vicleucel
RxNorm normalized name: idecabtagene vicleucel
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idecabtagene vicleucel (ide-cel) at doses of 150, 300, or 450 × 10^6 CAR T cells
Trial: 36794691
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) S-ICD implantation
Trial: 36794963
Drug: Emerade® 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerade® 500 μg
Trial: 36794963
Drug: Emerade® 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerade® 300 μg
Trial: 36794963
Drug: Epipen® 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epipen® 0.3 mg
Trial: 36795232
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) treatment at week 3
Trial: 36795232
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) treatment at week 12
Trial: 36795303
Drug: Structured clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured clinical pharmacist-delivered intervention (medication reconciliation and counselling at discharge, and two follow-up sessions at 4 and 8 weeks post-discharge)
Trial: 36795843
Drug: Darolutamide plus
RxNorm normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide plus androgen-deprivation therapy and docetaxel
Trial: 36795843
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus androgen-deprivation therapy and docetaxel
Trial: 36796016
Drug: Oral azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral azacitidine (CC-486) at 300 mg daily for 7 days before C1 of CHOP, and for 14 days before CHOP C2-6 plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Trial: 36796016
Drug: Oral azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral azacitidine (CC-486) plus CHOP
Trial: 36796498
Drug: Preoperative SABR
RxNorm normalized name: Sabril
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative SABR (Stereotactic Ablative Body Radiotherapy) for early-stage breast cancer, details on dosage and duration not available.
Trial: 36796641
Drug: Booster antenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster antenatal corticosteroids (12 mg betamethasone every 24 hours for 2 days)
Trial: 36797036
Drug: Pericapsular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pericapsular nerve group block (n=30) using 20 mL of adrenalized bupivacaine 0.50%
Trial: 36797036
Drug: Periarticular local
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular local anesthetic infiltration (n=30) using 60 mL of adrenalized bupivacaine 0.25%
Trial: 36797201
Drug: 15.5 g
RxNorm normalized name: ZINC OXIDE 15.5 g in 100 mL TOPICAL LOTION [Vacation SPF 30 Mineral]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15.5 g carbohydrates
Trial: 36797201
Drug: 31 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 31 g carbohydrates
Trial: 36797356
Drug: BGB-A333 alone
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BGB-A333 alone and in combination with tislelizumab
Trial: 36797394
Drug: Protective lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective lung ventilation (tidal volume set at 6 ml/Kg predicted body weight, PEEP 6 cmH2O)
Trial: 36797481
Drug: Tropifexor 10-90
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor 10-90 μg
Trial: 36797481
Drug: Tropifexor 140
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor 140 μg
Trial: 36797481
Drug: Tropifexor 200
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor 200 μg
Trial: 36797744
Drug: Rivoceranib (apatinib)
RxNorm normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoceranib (apatinib) 300 mg once daily in combination with pembrolizumab 200 mg every 3 weeks
Trial: 36797990
Drug: ETI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETI therapy (elexacaftor/tezacaftor/ivacaftor)
Trial: 36798001
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment for transient congenital hypothyroidism (TCH)
Trial: 36798001
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment for permanent congenital hypothyroidism (PCH)
Trial: 36798001
Drug: Levothyroxine dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine dose of ≤3.95, ≤2.56, ≤2.19 and ≤2.12 μg/kg/day at 6 months, 1, 2 and 3 years of follow-up respectively
Trial: 36798676
Drug: Four-session tobacco
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-session tobacco cessation intervention with nicotine replacement therapy (NRT)
Trial: 36798676
Drug: Re-engagement with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-engagement with Quitline treatment
Trial: 36798983
Drug: Sham-therapy with
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-therapy with ≥ 5 hours of sleep
Trial: 36799346
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation with mannitol
Trial: 36799958
Drug: Sertraline, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline, dosage and duration not specified
Trial: 36799961
Drug: Ketamine treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine treatment, dosage and duration not specified
Trial: 36800277
Drug: CortisolDST 83-137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CortisolDST 83-137 nmol/L
Trial: 36800277
Drug: CortisolDST ≥138
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CortisolDST ≥138 nmol/L
Trial: 36800277
Drug: CortisolDST 50-82
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CortisolDST 50-82 nmol/L in patients younger than 65 years
Trial: 36800443
Drug: SGN-CD228A (antibody-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGN-CD228A (antibody-drug conjugate with MMAE)
Trial: 36800982
Drug: BEAM program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEAM program (online group therapy and app-based mental health and parenting program)
Trial: 36801448
Drug: MSDC-0602K (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSDC-0602K (250 mg)
Trial: 36801448
Drug: MSDC-0602K treatment
RxNorm normalized name: MSDC-0160
DrugBank: Mitoglitazone (DB11721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSDC-0602K treatment in ZDF rats
Trial: 36802022
Drug: Palovarotene 5
RxNorm normalized name: palovarotene 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palovarotene 5 mg
Trial: 36802022
Drug: Palovarotene 10
RxNorm normalized name: palovarotene 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palovarotene 10 mg
Trial: 36802022
Drug: Palovarotene (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palovarotene (both doses)
Trial: 36802715
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg efpeglenatide
Trial: 36802715
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg efpeglenatide
Trial: 36803273
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (200,000 IU/1 ml of cholecalciferol)
Trial: 36803273
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (physiological saline (1 ml))
Trial: 36803647
Drug: Azithromycin-based two-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin-based two-drug therapy
Trial: 36803647
Drug: Azithromycin-based three-drug
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin-based three-drug therapy
Trial: 36803673
Drug: Evolutionary Systems
RxNorm normalized name: CENTELLA ASIATICA 0.3 mg in 3 TOPICAL CREAM [StemCell TeN 10 Revolutionary skin theraphy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolutionary Systems Therapy for Schizotypy (experimental treatment)
Trial: 36803673
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy and psychopharmacological treatment (control)
Trial: 36803737
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate solution (OCS) administered before surgery
Trial: 36803737
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate solution (OCS)
Trial: 36803835
Drug: Mindfulness-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based intervention (M-Body), eight weekly, 90-min group sessions
Trial: 36803837
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks of post-surgical systemic antibiotic therapy for implant-free infections
Trial: 36803837
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of post-surgical systemic antibiotic therapy for implant-free infections
Trial: 36803837
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of post-surgical systemic antibiotic therapy for residual implant-related infections
Trial: 36803837
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of post-surgical systemic antibiotic therapy for residual implant-related infections
Trial: 36803837
Drug: Post-surgical systemic
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-surgical systemic antibiotic therapy
Trial: 36803840
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg IV every 3 weeks for ≤96 weeks
Trial: 36803840
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg IV every 3 weeks for ≤96 weeks + BCG (50 mg) induction and maintenance
Trial: 36803840
Drug: BCG (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (50 mg) induction and maintenance
Trial: 36803992
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral ivermectin (600 µg/kg daily for 7 days)
Trial: 36803992
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies casirivimab and imdevimab (600 mg/600 mg)
Trial: 37778363
Drug: No study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study drug
Trial: 39748312
Drug: Zavegepant 10
RxNorm normalized name: zavegepant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zavegepant 10 mg nasal spray
Trial: 36804094
Drug: Baliforsen 100
RxNorm normalized name: Baliforsen
DrugBank: Baliforsen (DB17852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baliforsen 100 mg
Trial: 36804094
Drug: Baliforsen 200
RxNorm normalized name: Baliforsen
DrugBank: Baliforsen (DB17852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baliforsen 200 mg
Trial: 36804094
Drug: Baliforsen 300
RxNorm normalized name: Baliforsen
DrugBank: Baliforsen (DB17852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baliforsen 300 mg
Trial: 36804094
Drug: Baliforsen 400
RxNorm normalized name: Baliforsen
DrugBank: Baliforsen (DB17852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baliforsen 400 mg
Trial: 36804094
Drug: Baliforsen 600
RxNorm normalized name: Baliforsen
DrugBank: Baliforsen (DB17852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baliforsen 600 mg
Trial: 36804322
Drug: Moderate-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose group (4 mg total carotenoids/d, 177 mL orange-carrot juice/d)
Trial: 36804322
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (8 mg total carotenoids/d, 355 mL orange-carrot juice/d)
Trial: 36804322
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (negligible carotenoids, 177 mL apple juice/d)
Trial: 36804450
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care (CC) intervention including motivational interviewing and behavioral activation for 12 months
Trial: 36804834
Drug: BPaL regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPaL regimen (high-dose linezolid, bedaquiline, and pretomanid)
Trial: 36805083
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy with AAV8-LSPhGAA (1.6 × 10^13 vg/kg)
Trial: 36805095
Drug: Substantial protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substantial protein (≥0.4 g/kg/d) or calorie (≥5 kcal/kg/d) gap between targeted or actual intake
Trial: 37359884
Drug: Surf Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surf Therapy
Trial: 37359884
Drug: Hike Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hike Therapy
Trial: 36805672
Drug: Both Surf
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Surf and Hike Therapies
Trial: 36805707
Drug: Inhaled prostacyclin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled prostacyclin (3 times/day for 5 days)
Trial: 36805833
Drug: Ato-Dro 80-5
RxNorm normalized name: SKIN BARRIER WIPE ATOS SKIN TAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ato-Dro 80-5 mg
Trial: 36805833
Drug: Ato-Dro 80-10
RxNorm normalized name: SKIN BARRIER WIPE ATOS SKIN TAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ato-Dro 80-10 mg
Trial: 36806068
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (TCS) during an AD flare
Trial: 36806073
Drug: Smartphone app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Smartphone app (Airmid) with monthly questionnaires for 90 days
Trial: 36807215
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) applied to the first and second molars for 10 seconds per point at 16 different points.
Trial: 36807215
Drug: Contralateral side
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contralateral side of the intervention group (no laser treatment).
Trial: 36807273
Drug: Ultra-long 48
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-long 48 mm drug-eluting stent (DES)
Trial: 36807465
Drug: Ivermectin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (600 μg/kg daily for 6 days)
Trial: 36808045
Drug: Web-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive-behavioral therapy
Trial: 36808075
Drug: sitravatinib 120
RxNorm normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitravatinib 120 mg orally once daily plus tislelizumab 200 mg intravenously every 3 weeks
Trial: 36808074
Drug: hCART19 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hCART19 therapy
Trial: 36808074
Drug: hCART19 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hCART19 therapy with consolidation therapy
Trial: 36808186
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (rifampin and isoniazid for 24 weeks with pyrazinamide and ethambutol for the first 8 weeks)
Trial: 36808216
Drug: 12-g SCF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-g SCF + 600-mg calcium lactate gluconate (SCF + Ca)
Trial: 36808216
Drug: 12-g SCF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-g SCF
Trial: 36808216
Drug: 600-mg calcium
RxNorm normalized name: ubidecarenone 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600-mg calcium lactate gluconate (Ca)
Trial: 36808285
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (NIVO) 3 mg/kg every 2 weeks
Trial: 36808285
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + Ipilimumab (NIVO + IPI) 3 mg/kg + 1 mg/kg every 3 weeks (4 doses) followed by NIVO 3 mg/kg every 2 weeks
Trial: 36808891
Drug: Savolitinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib 600 mg (oral)
Trial: 36808891
Drug: Intravenous 100
RxNorm normalized name: immune globulin intravenous 100 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 100 μg of radiolabeled micro-tracer
Trial: 36808931
Drug: d-mannose (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-mannose (2 g/d)
Trial: 36808931
Drug: Control (Vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Vaginal Estrogen Therapy alone)
Trial: 36809018
Drug: mSTART (Mobile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mSTART (Mobile SafeTy And Recovery Therapy)
Trial: 36809018
Drug: START alone
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: START alone (without mobile augmentation)
Trial: 36809018
Drug: mSTART and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mSTART and START (regardless of mobile augmentation)
Trial: 36809050
Drug: Savolitinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savolitinib (600 mg once daily) and Durvalumab (1,500 mg once every four weeks)
Trial: 36809150
Drug: Serdexmethylphenidate/Dexmethylphenidate Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serdexmethylphenidate/Dexmethylphenidate Capsules
Trial: 36809195
Drug: Setanaxib 400
RxNorm normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setanaxib 400 mg twice daily (BID)
Trial: 36809195
Drug: Setanaxib 400
RxNorm normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setanaxib 400 mg once daily (OD)